During cancer treatment, a biopsy or a separate test sometimes returns an unfamiliar name — 'HER2 (human epidermal growth factor receptor 2)' — alongside a score such as 0, 1+, 2+, or 3+. Facing new words and numbers, it can be hard to tell whether the result is good or worrying, and the uncertainty is unsettling. This article does not promise the effect of any particular drug; instead, it aims to sketch the bigger picture of what such a result means and what conversations tend to follow.
HER2 is a protein on the cell surface, a bit like a 'signal antenna.' When there are far too many of these antennas (overexpression), a cell may receive growth signals more often than it should and multiply faster. To gauge this, the laboratory stains the tissue and visually assesses how much of the protein is present (immunohistochemistry, IHC), reporting the level as 0, 1+, 2+, or 3+. In general, 3+ is read as clear overexpression, while 0 and 1+ are read as not clearly overexpressed; an ambiguous 2+ may be confirmed with a further test at the gene level (in-situ hybridization, ISH/FISH).
This result matters because, even for cancer in the same location, the treatment options available can differ depending on whether such a 'biomarker' is present. Treatment designed to aim at a specific target is called 'targeted therapy,' and in recent years approaches such as the 'antibody-drug conjugate (ADC)' — which loads a cancer-fighting agent onto an antibody to deliver it more selectively to cells carrying the target — are being studied and used across several cancer types. However, which biomarker can be used in which cancer, at which stage, and under which conditions varies with each country's and each period's approval and reimbursement rules, and also with an individual's situation. So 'someone else used it' does not automatically mean 'it will work for me.'
Every treatment, targeted therapy included, carries the possibility of side effects alongside its benefits. In particular, with some treatments, inflammation of the lungs — 'interstitial lung disease (ILD)' — is recognized as a rare but important side effect. For that reason, if new changes appear during treatment, such as a dry cough you did not have before, breathlessness, unusual shortness of breath when climbing stairs, or fever, it is safer to tell your care team as soon as possible rather than saving it for the next visit. Reporting such signals early is not being over-anxious; it is cooperation that helps you continue treatment safely over the long run.
Waiting for test results can feel especially long. In that time, rather than unsettling yourself with vague online searches, it helps to write down questions to ask at your next appointment — for example, 'How did this marker turn out in my test?', 'What treatment options can be considered at this stage?', and 'What are the hopes and risks of each option, and which side-effect signals should I watch for?' Far more important than a single number is how that number is read within the whole picture and what is done about it.
This article is general information intended to aid understanding and cannot replace individual diagnosis or treatment. Please discuss the interpretation of test results and the choice of treatment with your care team.